BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/25/2025 4:19:44 PM | Browse: 179 | Download: 844
 |
Received |
|
2024-11-10 14:52 |
|
Peer-Review Started |
|
2024-11-10 14:52 |
|
First Decision by Editorial Office Director |
|
2024-12-21 22:15 |
|
Return for Revision |
|
2024-12-23 00:09 |
|
Revised |
|
2025-01-02 01:46 |
|
Publication Fee Transferred |
|
2025-01-09 14:03 |
|
Second Decision by Editor |
|
2025-02-18 02:37 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-02-18 08:23 |
|
Articles in Press |
|
2025-02-18 08:23 |
|
Edit the Manuscript by Language Editor |
|
2025-02-24 10:51 |
|
Typeset the Manuscript |
|
2025-03-07 07:25 |
|
Publish the Manuscript Online |
|
2025-03-25 16:19 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Chemistry, Medicinal |
| Manuscript Type |
Clinical Trials Study |
| Article Title |
Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yong Liu, Hong-Gen Liu and Cheng Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Scientific Research Project of Tianjin Municipal Education Commission |
2018KJ015 |
|
| Corresponding Author |
Cheng Zhao, Department of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, No. 88 Changling Road, Xiqing District, Tianjin 300000, China. chengzi0845_cn@sina.com |
| Key Words |
Gastric cancer; Recombinant human endostatin; Peritoneal metastasis; Malignant ascites; Cisplatin; Efficacy; Prognosis |
| Core Tip |
Recombinant human endostatin (RH-endostatin) is an angiogenesis-inhibiting drug; the present study demonstrates that the intraperitoneal perfusion of RH-endostatin prolongs the prognosis of patients with gastric cancer (GC) with malignant ascites, particularly in patients with small and moderate ascites volumes. Intraperitoneal RH-endostatin perfusion significantly improve the quality of life in patients with GC with ascites, with less toxicity. |
| Publish Date |
2025-03-25 16:19 |
| Citation |
Liu Y, Liu HG, Zhao C. Intraperitoneal perfusion of endostatin improves the effectiveness and prolongs the prognosis of patients with gastric cancer. World J Gastrointest Oncol 2025; 17(4): 103131 |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/103131.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.103131 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
